细胞和基因治疗生产品质控制市场－全球产业规模、份额、趋势、机会及预测（按治疗类型、产品、製程、技术、应用、地区和竞争格局划分），2021-2031年

全球细胞和基因治疗生产品管市场预计将从 2025 年的 13.5 亿美元成长到 2031 年的 20.1 亿美元，复合年增长率为 6.87%。

该领域着重严格的分析测试和监管合规流程，以检验先进医疗产品的安全性、有效性、纯度和特性。该市场的成长主要得益于临床试验数量的快速增加以及针对肿瘤和罕见遗传疾病的治疗方法监管核准速度的不断提高。这些因素使得实施全面的品质保证架构势在必行，以便在商业化规模生产中，既能应对生物製药的天然变异性，又能满足严格的安全标准。

根据美国基因与细胞治疗学会的数据，到2024年，全球在开发平臺将超过4000种，这将对专业检测通讯协定产生显着需求。儘管市场成长势头强劲，但仍面临许多挑战，包括开发标准化效力检测法的技术复杂性和高成本。这些挑战往往会延长生产週期，增加整体销货成本，阻碍因素市场扩张。

市场驱动因素

生物製药研发领域资金和投资的涌入，从根本上加速了细胞和基因治疗（CGT）领域先进品管方法的应用。随着研发人员努力将复杂的治疗方法商业化，大量资金正被投入到推进临床试验以及建立稳健、扩充性的生产和检测基础设施。这种雄厚的资金实力使企业能够购买高端分析设备，并检验符合监管要求的快速检测方法。据再生医学联盟（Alliance for Regenerative Medicine）称，该领域的资金筹措在2024年10月再次活跃起来，仅上半年全球投资就达到了109亿美元。这些资金对于克服生产瓶颈以及满足日益增加的后期候选药物不断变化的品管需求至关重要。

第二个关键驱动因素是将自动化和数数位化融入品管工作流程，这直接满足了产业对更高准确性和更少误差的需求。透过以自动化平台取代劳力密集的手动测试，製造商正在提高资料完整性，并缩短无菌性和有效性测试结果的报告时间。大型製药企业为获得自动化生产能力而进行的合作，充分体现了这种转变。例如，Fierce Pharma在2024年4月报道称，百时美施贵宝公司签署了一项价值3.8亿美元的协议，以确保在Cellares的全自动平台上获得独家生产能力。监管方面的进展进一步强化了这一趋势。例如，正如PharmaBoardroom在2024年4月报导的那样，预计2023年将有创纪录的7种细胞和基因治疗药物获得FDA核准，这凸显了满足商业性需求的自动化合规品管解决方案的紧迫性。

市场挑战

开发标准化的效力检测方法涉及复杂的技术要求和高昂的成本，这严重阻碍了全球细胞和基因治疗生产品管市场的发展。先进治疗方法固有的高生物变异性常常迫使製造商设计客製化的检测通讯协定来检验产品效力，而不是依赖现成的标准。这种缺乏标准化的做法导致了昂贵且耗时的研发週期，显着增加了产品成本 (COGS) 并延长了生产週期。这些问题常常导致监管审批延误，因为化学、生产和控制 (CMC) 方面的缺陷会阻碍产品进入商业化阶段，并妨碍透过广泛的品管检测产生收入。

2024年，再生医学联盟预计全球将有多达17种新型细胞和基因疗法获得监管部门核准，这将标誌着大量商业产品的涌入，并对品管系统构成巨大压力。然而，目前效力检测法的低效性造成了瓶颈，阻碍了此潜在产量的实现。因此，高昂的检测成本和技术壁垒正在延缓候选疗法向可规模化商业化生产的转化，直接阻碍了市场扩张。

市场趋势

一个显着的行业趋势是，由于复杂病毒载体和细胞疗法的表征技术要求高，生物製药公司越来越依赖将专业的品管测试外包给合约研发生产机构（CDMO）。生物製药公司不再为每种治疗方法建立高成本的内部测试体系，而是利用CDMO成熟的监管专业知识和可扩展的基础设施来加快批次放行。这种生产和测试资源的整合也反映在市场趋势中。例如，根据BioPharma Dive报道，Novo Holdings于2024年12月以165亿美元收购Catalent, Inc.，这表明该行业越来越依赖外部合作伙伴来管理日益增长的、规模更大、复杂性更高的先进疗法生产。

同时，人工智慧在预测性品质分析领域的应用正成为一股变革力量，它超越了简单的数位化，能够优化上游工程和下游流程。透过分析来自生物反应器的大量资料集，製造商利用机器学习演算法识别关键的品质偏差或代谢变化，从而在批次失效之前将其识别出来，保护宝贵的库存。鑑于自体疗法生产成本高昂，这种预测能力正变得至关重要。根据澳洲IT简报2025年9月发布的报告，生产错误带来的巨大财务风险——单一细胞疗法批次的成本可能超过50万美元——正推动着人工智慧驱动的即时监控技术在商业性可行性方面的应用。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球细胞与基因治疗生产品质管制市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依治疗方法（细胞疗法、基因疗法）
  • 依所提供服务的类型（设备、耗材、其他）
  • 按流程（原料准备、上游工程、下​​游加工、包装）
  • 透过技术（聚合酵素链锁反应（PCR）、流式细胞技术、鲎变形细胞裂解物（LAL）、酵素免疫分析法（ELISA）、层析法、质谱法、蛋白质印迹法、次世代定序（NGS）、电泳法、其他）
  • 按应用领域（安全性测试、有效性测试、鑑别测试、稳定性测试和遗传保真度测试等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美细胞与基因治疗生产品质管制市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲细胞和基因治疗生产品质控制市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区细胞与基因治疗生产品质控制市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲细胞与基因治疗生产品质控制市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美细胞与基因治疗生产品质管制市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球细胞与基因治疗生产品质管制市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bio-Techne Corporation
• Biomerieux SA
• F. Hoffmann-La Roche Ltd
• Lonza Group Ltd.
• Miltenyi Biotec India Pvt Ltd.
• Sartorius AG
• Thermo Fisher Scientific Inc.
• AGC Inc.
• Charles River Laboratories International, Inc.
• Merck KGaA

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Cell and Gene Therapy Manufacturing QC Market is projected to expand from USD 1.35 Billion in 2025 to USD 2.01 Billion by 2031, reflecting a compound annual growth rate of 6.87%. This sector focuses on stringent analytical testing and regulatory adherence processes designed to verify the safety, potency, purity, and identity of advanced medicinal products. The market is primarily underpinned by a surge in clinical trial volumes and an increasing rate of regulatory approvals for therapies targeting oncology and rare genetic disorders. These drivers necessitate the implementation of comprehensive quality assurance frameworks to manage the natural variability of biologic materials while ensuring rigorous safety standards are met during commercial scale-up.

Data from the American Society of Gene and Cell Therapy indicates that in 2024, the global development pipeline contained more than 4,000 therapeutic candidates, generating substantial demand for specialized testing protocols. Despite this robust growth trajectory, the market faces a significant obstacle regarding the technical complexity and high costs associated with creating standardized potency assays. These challenges often prolong production timelines and inflate the overall cost of goods sold, acting as a constraint on broader market expansion.

Market Driver

Significant capital inflows and investments in biopharmaceutical R&D are fundamentally accelerating the adoption of advanced quality control measures within the cell and gene therapy (CGT) sector. As developers strive to commercialize complex therapies, vast financial resources are being allocated to clinical progression as well as the establishment of robust, scalable manufacturing and testing infrastructures. This financial strength enables companies to acquire high-end analytical instruments and validate the rapid testing methods required for regulatory compliance. According to the Alliance for Regenerative Medicine, the sector saw a resurgence in financing in October 2024, with global investments reaching $10.9 billion in the first half of the year alone, funding that is crucial for overcoming manufacturing bottlenecks and aligning quality control evolution with the increasing number of late-stage candidates.

A second critical driver is the integration of automation and digitalization into quality control workflows, which directly addresses the industry's need for precision and error reduction. By replacing labor-intensive manual assays with automated platforms, manufacturers are enhancing data integrity and reducing turnaround times for sterility and potency results. This shift is exemplified by major pharmaceutical collaborations aiming to secure automated production capacities; for instance, Fierce Pharma reported in April 2024 that Bristol Myers Squibb signed a $380 million deal to reserve exclusive capacity on Cellares' fully automated platform. This trend is further reinforced by regulatory successes, such as the record seven new FDA approvals for cell and gene therapies in 2023 noted by PharmaBoardroom in April 2024, underscoring the urgency for automated, compliant QC solutions to meet commercial demand.

Market Challenge

The intricate technical requirements and high costs involved in developing standardized potency assays constitute a formidable barrier to the growth of the Global Cell and Gene Therapy Manufacturing QC Market. Due to the significant biological variability inherent in advanced therapies, manufacturers are often compelled to design bespoke testing protocols to verify product potency rather than utilizing off-the-shelf standards. This lack of standardization requires expensive, labor-intensive development cycles that significantly increase the overall cost of goods sold (COGS) and extend production timelines. These issues frequently lead to regulatory delays, as deficiencies in Chemistry, Manufacturing, and Controls (CMC) can prevent products from advancing to the commercial stage where high-volume quality control testing generates revenue.

In 2024, the Alliance for Regenerative Medicine anticipated up to 17 regulatory approvals for new cell and gene therapies globally, signaling an influx of commercial products that places acute pressure on quality control systems. However, the inefficiency of current potency assays creates a bottleneck that stifles this potential throughput. Consequently, market expansion is directly impeded, as high testing costs and technical hurdles slow the transition of therapeutic candidates into scalable commercial production.

Market Trends

A dominant trend in the industry is the increasing reliance on outsourcing specialized QC assays to Contract Development and Manufacturing Organizations (CDMOs), driven by the technical demands of characterizing complex viral vectors and cell therapies. Rather than constructing expensive in-house testing capabilities for every modality, biopharmaceutical companies are leveraging the established regulatory expertise and scalable infrastructure of CDMOs to accelerate batch release. This consolidation of manufacturing and testing resources is illustrated by significant market movements, such as Novo Holdings' pivotal $16.5 billion acquisition of Catalent in December 2024, as reported by BioPharma Dive, which underscores the sector's strategic reliance on external partners to manage the growing volume and complexity of advanced therapeutic production.

Simultaneously, the application of artificial intelligence for predictive quality analytics is emerging as a transformative force, moving beyond simple digitization to optimize both upstream and downstream processes. Manufacturers are utilizing machine learning algorithms to analyze vast datasets from bioreactors, allowing for the identification of critical quality deviations and metabolic shifts before they result in batch failure, thereby protecting expensive inventory. This predictive capability is becoming financially imperative given the high costs associated with manufacturing autologous treatments; according to IT Brief Australia in September 2025, the substantial financial risk of production errors-where a single cell therapy batch can cost upwards of $500,000-is driving the adoption of AI-driven real-time monitoring for commercial viability.

Key Market Players

• Bio-Techne Corporation
• Biomerieux SA
• F. Hoffmann-La Roche Ltd
• Lonza Group Ltd.
• Miltenyi Biotec India Pvt Ltd.
• Sartorius AG
• Thermo Fisher Scientific Inc.
• AGC Inc.
• Charles River Laboratories International, Inc.
• Merck KGaA

Report Scope

In this report, the Global Cell and Gene Therapy Manufacturing QC Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell and Gene Therapy Manufacturing QC Market, By Therapy Type

• Cell Therapy
• Gene Therapy

Cell and Gene Therapy Manufacturing QC Market, By Offering

• Instruments
• Consumables
• Others

Cell and Gene Therapy Manufacturing QC Market, By Process

• Raw Material Preparation
• Upstream Processing
• Downstream Processing
• Packaging

Cell and Gene Therapy Manufacturing QC Market, By Technology

• Polymerase Chain Reaction (PCR)
• Flow Cytometry
• Limulus Amebocyte Lysate (LAL)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Chromatography
• Mass Spectrometry
• Western Blotting
• Next-Generation Sequencing (NGS)
• Electrophoresis
• Others

Cell and Gene Therapy Manufacturing QC Market, By Application

• Safety Testing
• Potency Testing
• Identity Testing
• Stability and Genetic Fidelity Testing
• Others

Cell and Gene Therapy Manufacturing QC Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell and Gene Therapy Manufacturing QC Market.

Available Customizations:

Global Cell and Gene Therapy Manufacturing QC Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell and Gene Therapy Manufacturing QC Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type (Cell Therapy, Gene Therapy)
  • 5.2.2. By Offering (Instruments, Consumables, Others)
  • 5.2.3. By Process (Raw Material Preparation, Upstream Processing, Downstream Processing, Packaging)
  • 5.2.4. By Technology (Polymerase Chain Reaction (PCR), Flow Cytometry, Limulus Amebocyte Lysate (LAL), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Mass Spectrometry, Western Blotting, Next-Generation Sequencing (NGS), Electrophoresis, Others)
  • 5.2.5. By Application (Safety Testing, Potency Testing, Identity Testing, Stability and Genetic Fidelity Testing, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Cell and Gene Therapy Manufacturing QC Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Offering
  • 6.2.3. By Process
  • 6.2.4. By Technology
  • 6.2.5. By Application
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cell and Gene Therapy Manufacturing QC Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Offering
      • 6.3.1.2.3. By Process
      • 6.3.1.2.4. By Technology
      • 6.3.1.2.5. By Application
  • 6.3.2. Canada Cell and Gene Therapy Manufacturing QC Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Offering
      • 6.3.2.2.3. By Process
      • 6.3.2.2.4. By Technology
      • 6.3.2.2.5. By Application
  • 6.3.3. Mexico Cell and Gene Therapy Manufacturing QC Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Offering
      • 6.3.3.2.3. By Process
      • 6.3.3.2.4. By Technology
      • 6.3.3.2.5. By Application

7. Europe Cell and Gene Therapy Manufacturing QC Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy Type
  • 7.2.2. By Offering
  • 7.2.3. By Process
  • 7.2.4. By Technology
  • 7.2.5. By Application
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Offering
      • 7.3.1.2.3. By Process
      • 7.3.1.2.4. By Technology
      • 7.3.1.2.5. By Application
  • 7.3.2. France Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Offering
      • 7.3.2.2.3. By Process
      • 7.3.2.2.4. By Technology
      • 7.3.2.2.5. By Application
  • 7.3.3. United Kingdom Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Offering
      • 7.3.3.2.3. By Process
      • 7.3.3.2.4. By Technology
      • 7.3.3.2.5. By Application
  • 7.3.4. Italy Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy Type
      • 7.3.4.2.2. By Offering
      • 7.3.4.2.3. By Process
      • 7.3.4.2.4. By Technology
      • 7.3.4.2.5. By Application
  • 7.3.5. Spain Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy Type
      • 7.3.5.2.2. By Offering
      • 7.3.5.2.3. By Process
      • 7.3.5.2.4. By Technology
      • 7.3.5.2.5. By Application

8. Asia Pacific Cell and Gene Therapy Manufacturing QC Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Offering
  • 8.2.3. By Process
  • 8.2.4. By Technology
  • 8.2.5. By Application
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Offering
      • 8.3.1.2.3. By Process
      • 8.3.1.2.4. By Technology
      • 8.3.1.2.5. By Application
  • 8.3.2. India Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Offering
      • 8.3.2.2.3. By Process
      • 8.3.2.2.4. By Technology
      • 8.3.2.2.5. By Application
  • 8.3.3. Japan Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Offering
      • 8.3.3.2.3. By Process
      • 8.3.3.2.4. By Technology
      • 8.3.3.2.5. By Application
  • 8.3.4. South Korea Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy Type
      • 8.3.4.2.2. By Offering
      • 8.3.4.2.3. By Process
      • 8.3.4.2.4. By Technology
      • 8.3.4.2.5. By Application
  • 8.3.5. Australia Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy Type
      • 8.3.5.2.2. By Offering
      • 8.3.5.2.3. By Process
      • 8.3.5.2.4. By Technology
      • 8.3.5.2.5. By Application

9. Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Offering
  • 9.2.3. By Process
  • 9.2.4. By Technology
  • 9.2.5. By Application
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cell and Gene Therapy Manufacturing QC Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Offering
      • 9.3.1.2.3. By Process
      • 9.3.1.2.4. By Technology
      • 9.3.1.2.5. By Application
  • 9.3.2. UAE Cell and Gene Therapy Manufacturing QC Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Offering
      • 9.3.2.2.3. By Process
      • 9.3.2.2.4. By Technology
      • 9.3.2.2.5. By Application
  • 9.3.3. South Africa Cell and Gene Therapy Manufacturing QC Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Offering
      • 9.3.3.2.3. By Process
      • 9.3.3.2.4. By Technology
      • 9.3.3.2.5. By Application

10. South America Cell and Gene Therapy Manufacturing QC Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy Type
  • 10.2.2. By Offering
  • 10.2.3. By Process
  • 10.2.4. By Technology
  • 10.2.5. By Application
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cell and Gene Therapy Manufacturing QC Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy Type
      • 10.3.1.2.2. By Offering
      • 10.3.1.2.3. By Process
      • 10.3.1.2.4. By Technology
      • 10.3.1.2.5. By Application
  • 10.3.2. Colombia Cell and Gene Therapy Manufacturing QC Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy Type
      • 10.3.2.2.2. By Offering
      • 10.3.2.2.3. By Process
      • 10.3.2.2.4. By Technology
      • 10.3.2.2.5. By Application
  • 10.3.3. Argentina Cell and Gene Therapy Manufacturing QC Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy Type
      • 10.3.3.2.2. By Offering
      • 10.3.3.2.3. By Process
      • 10.3.3.2.4. By Technology
      • 10.3.3.2.5. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cell and Gene Therapy Manufacturing QC Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bio-Techne Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Biomerieux SA
• 15.3. F. Hoffmann-La Roche Ltd
• 15.4. Lonza Group Ltd.
• 15.5. Miltenyi Biotec India Pvt Ltd.
• 15.6. Sartorius AG
• 15.7. Thermo Fisher Scientific Inc.
• 15.8. AGC Inc.
• 15.9. Charles River Laboratories International, Inc.
• 15.10. Merck KGaA

16. Strategic Recommendations

17. About Us & Disclaimer